Successful treatment of psoriasis with topical application of active vitamin D3 analogue, 1α, 24-dihydroxycholecalciferol

Kato, Toyoaki; Rokugo, Masaaki; Terada, Tadashi; Tagami, Hachiro

doi:10.1111/j.1365-2133.1986.tb06237.x

Cited by 126 publications

(30 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmacological doses of 1,25(OH) 2 D 3 induce hypercalcemia when administered systemically, which is a significant obstacle when considering its clinical application. However tacalcitol ointment and cream preparations have been prescribed successfully for the treatment of psoriasis [15,16,31]. In this case, administration via the topical route delivers a higher concentration of the drug to epidermal lesions [32] than could be achieved using a systemic route.…”

Section: Discussionmentioning

confidence: 99%

Tacalcitol, an Active Vitamin D<sub>3</sub>, Induces Nerve Growth Factor Production in Human Epidermal Keratinocytes

Fukuoka

Sakurai

Ohta

et al. 2001

Skin Pharmacol Physiol

View full text Add to dashboard Cite

The human epidermal keratinocyte cell line K-TL-1, developed from a benign epidermal tumor, was cultured in the presence of the synthetic vitamin D₃ analogue tacalcitol [1α,24(R)-dihydroxyvitamin D₃] to assess the effects on the production of nerve growth factor (NGF). Confluent K-TL-1 cells were cultured with 10^–8M of tacalcitol. Supernatants and cell homogenates were collected and NGF concentrations were determined by enzyme-linked immunosorbent assay. The concentration of NGF in the supernatants of cultures treated with tacalcitol peaked within 24 h after the start of tacalcitol treatment and remained stable for 96 h. This NGF induction caused by tacalcitol was dose-dependent, showing an ED₅₀ between 10^–10 and 10^–9M. Induction of NGF mRNA expression by tacalcitol was also observed by RT-PCR, indicating that tacalcitol induced NGF expression through transcriptional activation. These results suggest that active vitamin D₃ could treat peripheral neuropathy by inducing NGF production in the skin.

show abstract

Section: Discussionmentioning

confidence: 99%

Tacalcitol, an Active Vitamin D<sub>3</sub>, Induces Nerve Growth Factor Production in Human Epidermal Keratinocytes

Fukuoka

Sakurai

Ohta

et al. 2001

Skin Pharmacol Physiol

View full text Add to dashboard Cite

show abstract

“…Dysfunctional growth and differentiation of epidermal cells combined with an inflammatory immune response are key elements in the development of psoriasis [7]. The demonstrated effects of calcitriol on these factors, therefore, led to its investigation for the control of psoriasis and it has now been shown that calcitriol and a number of analogues, principally calcipotriol, are effective therapies for psoriasis [3, 8, 9, 10, 11]. …”

Section: Introductionmentioning

confidence: 99%

The Efficacy, Safety and Tolerance of Calcitriol 3 μg/g Ointment in the Treatment of Plaque Psoriasis: A Comparison with Short-Contact Dithranol

2000

View full text Add to dashboard Cite

Objective: A comparison of efficacy, safety and tolerance of a twice-daily application of calcitriol 3 μg/g ointment with dithranol cream. Methods: The study was an 8-week, prospective, randomised, open, parallel-group trial with 114 patients. Subjects received either 3 μg/g calcitriol ointment (twice daily) or 0.25–2% dithranol cream (once daily for 30 min). Results were measured using global improvement, global severity, PASI, quality of life (QOL) and Psoriasis Disability Index scores. Safety was determined from reports of adverse events and blood chemistry analysis. Results: At final assessment, calcitriol and dithranol were comparably efficacious. Skin irritation was reported by 5% of calcitriol and 72% of dithranol patients. Patients rated QOL and overall acceptability of calcitriol more highly. Conclusions: Twice-daily calcitriol ointment (3 μg/g) is equally effective as a once-daily, short-contact dithranol regimen. However, calcitriol is better tolerated than dithranol, and provides a better QOL and a greater patient acceptability.

show abstract

“…1.24 dihydroxycholecalciferol appeared to be effective when used topically (27), but this compound is almost as active as calcitriol in mineral metabolism.…”

Section: Effcwymentioning

confidence: 99%

Progress in self treatment for psoriasis vulgaris

Berth‐Jones

Hutchinson

1992

Journal of Clinical Pharmacy and Therapeutics

View full text Add to dashboard Cite

SUMMARY Chronic plaque psoriasis is by far the most frequent form of the disease and is usually amenable to home treatment. The therapeutic armamentarium for self‐treatment of psoriasis has, until recently, been limited to emollients, tar, dithranol and topical corticosteroids. Although limited progress has been made in improving formulations and treatment regimes for these compounds, they still have significant drawbacks in terms of either unwanted effects or cosmetic acceptability. Topical vitamin D analogues offer a new, effective, convenient and safe option for self‐treatment of psoriasis. Most research has been performed on calcipotriol. This has compared well to betamethasone valerate and short‐contact dithranol in controlled studies. Skin irritation is frequently noticed by patients, but rarely requires treatment to be discontinued. The mechanism of action appears most likely to be a direct regulation of keratinocyte proliferation and differentiation. Calcipotriol has relatively little effect on calcium metabolism and appears to be safe when used according to established guidelines but hypercalcaemia may develop if excessive quantities are used.

show abstract

Successful treatment of psoriasis with topical application of active vitamin D3 analogue, 1α, 24-dihydroxycholecalciferol

Cited by 126 publications

References 6 publications

Tacalcitol, an Active Vitamin D<sub>3</sub>, Induces Nerve Growth Factor Production in Human Epidermal Keratinocytes

Tacalcitol, an Active Vitamin D<sub>3</sub>, Induces Nerve Growth Factor Production in Human Epidermal Keratinocytes

The Efficacy, Safety and Tolerance of Calcitriol 3 μg/g Ointment in the Treatment of Plaque Psoriasis: A Comparison with Short-Contact Dithranol

Progress in self treatment for psoriasis vulgaris

Contact Info

Product

Resources

About